Navy's Next-Gen Binoculars Will Recognize Your Face

Take a close look, because the next generation of military binoculars could be doing more than just letting sailors and soldiers see from far away. The Navy now wants binoculars that can scan and recognize your face from 650 feet away.

That’s according to a Jan. 16 contract announcement from the Navy’s Space and Naval Warfare Systems Command, which is seeking a “Wireless 3D Binocular Face Recognition System.” During a testing period of 15 months, the plan is to improve “stand-off identification of uncooperative subjects” during daylight, using binoculars equipped with scanners that can read your mug from “100 to 200 meters” away, or about 328 to 650 feet. After scanning your mug, the binoculars then transmit the data to a database over a wireless network, where the data is then analyzed to determine a person’s identity. The no-bid contract, for an unspecified amount of money, went to California biometrics firm StereoVision Imaging.

“High level, it’s a surveillance and identification system,” Greg Steinthal, StereoVision’s president, tells Danger Room. “It’s using the ubiquitous binocular for real-time identification. The data point here is that this is to be used to add objectivity to an operation that’s highly subjective. So this is not intended for kinetic action to go arrest or detain someone. It’s more a tool to put other eyes on him or her.”

It helps that the technology — at least in a more limited form — already exists. StereoVision has developed a face-recognizing binocular system called 3DMobileID, with a maximum distance of around 328 feet, or 100 meters. “You have an unfair advantage,” the company touts in one promotional video, showing images of a human face being scanned at a distance, before the background is stripped out for a blue screen and then matched up to a database.

Depending on how well the binoculars work — and there’s reason to be cautious — it could give the Navy the ability to take advanced facial recognition into a much more portable and long-distance version than many current systems. Facebook uses the technology to match faces when users upload new photos. Google has its own version as well for its its Picasa photo service, and Apple has been researching face recognition as a way to unlock smartphones. (There are apps for iOS that do this, too.)

But the ranges on most systems also tend to max out at a few feet. For the military, that can be dangerous. Close-range biometric scanners (iris scanners are currently used by soldiers in Afghanistan) can pose a danger to the operator, as a person walking up to have their features scanned from a few inches away could be preparing to detonate an explosive vest. And what if a person happens to be on the move, or is bobbing and weaving through a crowd? That can render the scanners ineffective. Once upon a time, many face scanners also depended on the relatively crude practice of scanning 2-D images of the human face, which are an imprecise method when there are varying lighting conditions.

But the key to solving many of these problems could be a simple upgrade: StereoVision’s system scans in 3-D. When the system first scans you, it creates a 3-D model of your face instead of a 2-D image. That allows the system to isolate your face from a crowd, sharpen the image — which boosts the range — and then compares the image to a database. A filter also adjusts for varying degrees of light by smoothing out light across the face into a uniform pattern.

Now for the flaws in the system. The binoculars are not intended to work at night, and have difficulty scanning faces in twilight. When the binoculars can’t draw an image, it gives off a an audible beep to the operator, which is helpful. Otherwise, the process takes “about five to 10 seconds,” says Steinthal.

It’s also less effective when a subject is on the move. “[It] depends on how fast the target is walking,” Steinthal says. “We’re at walking, one-and-half meters per second. Somebody running? We’re not going to be able to do that right now.”

The concept of binoculars that scan and identify is also — perhaps unnervingly — not limited to the military. For one, StereoVision’s binoculars were developed in part with a $409,226 contract from the National Institute of Justice, and face scanners are a popular research topic for the FBI more broadly.

The FBI is spending $1 billion on a program called Next Generation Identification based around developing face scanners and combining the technology with other biometrics like the iris, voice, and fingerprints. A static face recognition system has also been installed at Toucumen International Airport in Panama City that can scan travelers’ faces and match them to criminal databases maintained by the FBI and Interpol. The Los Angeles County Sheriff’s Department and the San Diego Police Department have also tested out the binoculars, according to Steinthal, and are intended there for gang enforcement units and even to track “celebrity stalkers” in the L.A. area. Maybe if the FBI wants its special agents to also have some pretty far-out binoculars too, it should take a peek.

Read More..

Well: Expressing the Inexpressible

When Kyle Potvin learned she had breast cancer at the age of 41, she tracked the details of her illness and treatment in a journal. But when it came to grappling with issues of mortality, fear and hope, she found that her best outlet was poetry.

How I feared chemo, afraid
It would change me.
It did.
Something dissolved inside me.
Tears began a slow drip;
I cried at the news story
Of a lost boy found in the woods …
At the surprising beauty
Of a bright leaf falling
Like the last strand of hair from my head

Ms. Potvin, now 47 and living in Derry, N.H., recently published “Sound Travels on Water” (Finishing Line Press), a collection of poems about her experience with cancer. And she has organized the Prickly Pear Poetry Project, a series of workshops for cancer patients.

“The creative process can be really healing,” Ms. Potvin said in an interview. “Loss, mortality and even hopefulness were on my mind, and I found that through writing poetry I was able to express some of those concepts in a way that helped me process what I was thinking.”

In April, the National Association for Poetry Therapy, whose members include both medical doctors and therapists, is to hold a conference in Chicago with sessions on using poetry to manage pain and to help adolescents cope with bullying. And this spring, Tasora Books will publish “The Cancer Poetry Project 2,” an anthology of poems written by patients and their loved ones.

Dr. Rafael Campo, an associate professor of medicine at Harvard, says he uses poetry in his practice, offering therapy groups and including poems with the medical forms and educational materials he gives his patients.

“It’s always striking to me how they want to talk about the poems the next time we meet and not the other stuff I give them,” he said. “It’s such a visceral mode of expression. When our bodies betray us in such a profound way, it can be all the more powerful for patients to really use the rhythms of poetry to make sense of what is happening in their bodies.”

On return visits, Dr. Campo’s patients often begin by discussing a poem he gave them — for example, “At the Cancer Clinic,” by Ted Kooser, from his collection “Delights & Shadows” (Copper Canyon Press, 2004), about a nurse holding the door for a slow-moving patient.

How patient she is in the crisp white sails
of her clothes. The sick woman
peers from under her funny knit cap
to watch each foot swing scuffing forward
and take its turn under her weight.
There is no restlessness or impatience
or anger anywhere in sight. Grace
fills the clean mold of this moment
and all the shuffling magazines grow still.

In Ms. Potvin’s case, poems related to her illness were often spurred by mundane moments, like seeing a neighbor out for a nightly walk. Here is “Tumor”:

My neighbor walks
For miles each night.
A mantra drives her, I imagine
As my boys’ chant did
The summer of my own illness:
“Push, Mommy, push.”
Urging me to wind my sore feet
Winch-like on a rented bike
To inch us home.
I couldn’t stop;
Couldn’t leave us
Miles from the end.

Karin Miller, 48, of Minneapolis, turned to poetry 15 years ago when her husband developed testicular cancer at the same time she was pregnant with their first child.

Her husband has since recovered, and Ms. Miller has reviewed thousands of poems by cancer patients and their loved ones to create the “Cancer Poetry Project” anthologies. One poem is “Hymn to a Lost Breast,” by Bonnie Maurer.

Oh let it fly
let it fling
let it flip like a pancake in the air
let it sing: what is the song
of one breast flapping?

Another is “Barn Wish” by Kim Knedler Hewett.

I sit where you can’t see me
Listening to the rustle of papers and pills in the other room,
Wondering if you can hear them.
Let’s go back to the barn, I whisper.
Let’s turn on the TV and watch the Bengals lose.
Let’s eat Bill’s Doughnuts and drink Pepsi.
Anything but this.

Ms. Miller has asked many of her poets to explain why they find poetry healing. “They say it’s the thing that lets them get to the core of how they are feeling,” she said. “It’s the simplicity of poetry, the bare bones of it, that helps them deal with their fears.”

---

Have you written a poem about cancer? Please share them with us in the comments section below.

Read More..

DealBook: Dell Nears a Buyout Deal of More Than $23 Billion

Dell Inc. neared an agreement on Monday to sell itself to a group led by its founder and the investment firm Silver Lake for more than $23 billion, people briefed on the matter said, in what would be the biggest buyout since the financial crisis.

If completed, a takeover would be the most ambitious attempt yet by Michael S. Dell to revive the company that bears his name. Such is the size of the potential deal that Mr. Dell has called upon Microsoft, one of his most important business partners, to shore up the proposal with additional financial muscle. The question will now turn to whether taking the personal computer maker private will accomplish what years of previous turnaround efforts have not.

The final details were being negotiated on Monday evening, and a deal could be announced as soon as Tuesday. Still, last-minute obstacles could cause the talks to collapse, the people briefed on the matter cautioned.

The consortium is expected to pay $13.50 to $13.75 a share, these people said. Mr. Dell is expected to contribute his nearly 16 percent stake to the deal, worth about $3.8 billion under the current set of terms. He is also expected to contribute hundreds of millions of dollars in fresh capital from his own fortune.

Silver Lake, known as one of the biggest investors in technology companies, would most likely contribute roughly $1 billion, these people added. Microsoft is expected to put in about $2 billion, though that would probably come in the form of preferred shares or debt.

Dell is also expected to bring home some of the cash that it holds in offshore accounts to help with the financing.

A spokesman for Dell declined to comment.

For decades, Dell benefited from its status as a pioneer in the market for personal computers. Founded in 1984 in a dormitory room at the University of Texas, the company grew into one of the biggest computer makers in the world, built on the simple premise that customers would flock to customize their machines.

By the late 1990s, its fast-rising stock created a company worth $100 billion and minted a class of “Dellionaires” whose holdings made for big fortunes, at least on paper. Mr. Dell amassed an estimated $16 billion and formed a quietly powerful investment firm to manage those riches.

But growing competition has sapped Dell’s strength. Rivals like Lenovo and Samsung have made the PC-making business less profitable. Last month, the market research firm Gartner reported that Dell sold 37.6 million PCs worldwide in 2012, a 12.3 percent drop from the previous year’s shipments. Perhaps more significant is the emergence of the smartphone and the tablet, two classes of devices that have eaten away at sales of traditional computers.

Mr. Dell has sought to move the company into the more lucrative and stable business of providing corporations with software services, spending billions of dollars on acquisitions to lead that transformation. The aim is to refashion Dell into something more like I.B.M. or Oracle. Even so, manufacturing PCs still makes up half of the company’s business.

The company’s stock had fallen 59 percent in the 10 years ended Jan. 11, the last business day before word of the buyout talks emerged. That has actually made Dell more tempting as a takeover target for its founder and Silver Lake, which see it as undervalued.

A Dell deal would be a watershed moment for the leveraged buyout industry: It would be the largest takeover since the Blackstone Group paid $26 billion for Hilton Hotels in the summer of 2007. No leveraged buyout since the financial crisis has surpassed the $7.2 billion that Kohlberg Kravis Roberts and others paid for the Samson Investment Company, an oil and gas driller, in the fall of 2011.

Private equity executives have hungered for the chance to strike a deal worth more than $10 billion, an accomplishment believed difficult because of the sheer size of financing required. Dell would take on more than $15 billion in debt, an enormous amount arranged by no fewer than four banks.

But the debt markets have been soaring over the last two years, as the cost of junk bonds has stayed low. Persistent low interest rates have prompted debt buyers to seek investments that carry higher yields

Dell was unusually well-placed to make a deal with private equity. The company carries $4.9 billion in long-term debt, which some analysts have regarded as a manageable amount. And its management has signaled a willingness to bring back at least some of the company’s cash hoard held overseas, despite potentially ringing up a hefty tax bill.

It is unclear whether the company’s biggest investors will accept a deal at the levels that the buyer consortium is advocating. Shares of Dell fell 2.6 percent, to $13.27, on Monday after reports of the proposed price range emerged.

Biggest Private Equity-Backed Leveraged Buyouts

DEAL, IN BILLIONS	TARGET	BUYER	ANNOUNCED
Source: Thomson Reuters *At time of deal, including assumption of debt, not adjusted for inflation.
$44.3	TXU	Morgan Stanley, Citigroup, Lehman Brothers Holdings, Kohlberg Kravis Roberts, Texas Pacific Group and Goldman Sachs	February 2007
37.7	Equity Office Properties Trust	Blackstone Group	November 2006
32.1	HCA	Bain Capital, Kohlberg Kravis Roberts and Merrill Lynch Global Private	July 2006
30.2	RJR Nabisco	Kohlberg Kravis Roberts	October 1988
30.1	BAA	Grupo Ferrovial SA, Caisse de Depot et Placement and GIC Special Invest	March 2006
27.6	Harrah’s Entertainment	Texas Pacific Group and Apollo Management	October 2006
27.4	Kinder Morgan	GS Capital Partners, The Carlyle Group and Riverstone Holdings	May 2006
27.2	Alltel	TPG Capital and GS Capital Partners	May 2007
27.0	First Data	Kohlberg Kravis Roberts	April 2007
26.7	Hilton Hotels	Blackstone Group	July 2007

Read More..

'American Sniper' Chris Kyle shot dead in a post-combat world

Military sniper Chris Kyle had survived the dust-worn places where he had to worry about enemy fire — or even friendly fire — until this weekend.

Kyle, 38, an author and former Navy SEAL, was shot dead Saturday by an unemployed, 25-year-old Marine veteran, Texas officials said Sunday. Kyle's friend Chad Littlefield, 35, was also killed. No one witnessed the shootings, authorities said.

The suspect, Eddie Ray Routh, used a semiautomatic handgun to shoot Kyle and Littlefield multiple times at a secluded gun range at the Rough Creek Lodge southwest of Fort Worth, investigators said at a televised news conference. Routh is in custody and is expected to face two capital murder charges.

Routh had enlisted in the Marines in 2006, deploying to Iraq in 2007 and to Haiti in 2010 for hurricane relief. He remains in the Marine Reserve.

After Kyle left the Navy in 2009, he wrote "American Sniper: The Autobiography of the Most Lethal Sniper in U.S. Military History." During his four deployments to Iraq, he wrote, he'd recorded the most confirmed kills of any American sniper — more than 150.

Back in the States, Kyle was known to take troubled veterans to gun ranges as part of giving back — shooting and hanging out as a kind of therapy.

"The shooter is possibly one of those people," Erath County Sheriff Tommy Bryant said at the news conference, hinting that Routh's mother, a schoolteacher, may have reached out to Kyle to get help for her son. Officials couldn't confirm whether Routh had suffered from post-traumatic stress disorder.

Routh appeared to be one of the nation's numerous unemployed veterans, and Kyle was one of those who left the anonymity of military service and entered the public sphere.

Kyle's autobiography was unapologetically politically incorrect: During one visit home between deployments, he got a tattoo of a crusader cross on his arm.

"I wanted everyone to know I was a Christian," Kyle wrote. "I had it put in in red, for blood. I hated the damn savages I'd been fighting. I always will. They've taken so much from me."

Kyle won adulation and a spotlight and appeared on the NBC reality show "Stars Earn Stripes," in which "celebrities are challenged to execute complicated missions inspired by real military exercises."

In an interview last year with Fox News' Bill O'Reilly, Kyle claimed to have punched former Minnesota Gov. Jesse Ventura in 2006 for "bad-mouthing the war, bad-mouthing Bush and bad-mouthing America."

Kyle was president of Craft International, a military and law enforcement training company. In a statement lamenting the slayings, the company identified Littlefield as Kyle's trusted friend and said they died trying to help "a troubled veteran."

News of Kyle's demise spread quickly through the Navy SEAL community, according to Rorke Denver, a reserve SEAL team lieutenant commander based in San Diego, who served with Kyle on SEAL Team 3 in Iraq.

"We're such a small brotherhood that when something happens to anybody here or overseas, word travels fast," Denver said Sunday.

Denver said the news was "really hard to believe," and he called Kyle "one of our real champions and battle stars."

"I knew Chris had been working with other veterans, folks with PTSD, trying to help them get better," Denver said. "It's hard to stomach that someone he was trying to help would turn on him."

Denver said he had been fielding questions from civilians who couldn't understand why Kyle would have taken someone with PTSD to a shooting range — but as a veteran, he understands.

"That type of shooting can actually be cathartic, calming," Denver said, "letting your heart settle," particularly for veterans who have just returned home after being accustomed to carrying weapons.

Officials said they didn't have a motive for Routh's attack. The three men apparently traveled to the gun range together in the same truck.

Read More..

Wired Science Space Photo of the Day: Wheatley Crater on Venus

Magellan radar image of Wheatley crater on Venus. This 72 km diameter crater shows a radar bright ejecta pattern and a generally flat floor with some rough raised areas and faulting. The crater is located in Asteria Regio at 16.6N,267E.

Image: NASA/GSFC [high-resolution]

Caption: NASA

Read More..

The top films at the North American Box Office

LOS ANGELES (Reuters) – Following are the top 10 movies at North American box offices for the weekend starting February 1, led by Warm Bodies at No. 1, according to studio estimates compiled by Reuters. 1 (*) Warm Bodies…………………………..$ 20.0 million 2 (1) Hansel and Gretel……………………..$ 9.2 million 3 (3) Silver Linings Playbook………………..$ 8.1 million 4 (2) Mama…………………………………$ 6.7 million 5 (4) Zero Dark Thirty………………………$ 5.3 million 6 (*) Bullet to the Head…………………….$ 4.5 million 7 (5) Parker……………………………….$ 3.2 million 8 (6) Django Unchained………………………$ 3.0 million 9 (10)Les Miserables………………………..$ 2.4 million 10 (11)Lincoln………………………………$ 2.4 million NOTES: (*) = new release

CUMULATIVE TOTALS: Lincoln…………………………………..$ 170.8 million Django Unchained…………………………..$ 151.0 million Les Miserables…………………………….$ 141.5 million Silver Linings Playbook…………………….$ 80.4 million Zero Dark Thirty…………………………..$ 77.8 million Mama……………………………………..$ 58.3 million Hansel and Gretel: Witch Hunters…………….$ 34.5 million Warm Bodies……………………………….$ 20.0 million Parker……………………………………$ 12.4 million Bullet to the Head…………………………$ 4.5 million

“Hansel & Gretel: Witch Hunters” was distributed by Paramount Pictures, a unit of Viacom Inc. “Zero Dark Thirty” was released by Sony Corp’s movie studio. “Warm Bodies” and “The Last Stand” were distributed by Lions Gate Entertainment. “Bullet to the Head” was released by Warner Bros, a unit of Time Warner Inc “Django Unchained” and “Silver Linings Playbook” were distributed by Weinstein Co. “Les Miserables” and “Mama” were distributed by Universal Pictures, a unit of Comcast Corp.

(Reporting By Ronald Grover and Andrea Burzynski; Editing by Sandra Maler)

Movies News Headlines – Yahoo! News

Title Post: The top films at the North American Box Office
Url Post: http://www.news.fluser.com/the-top-films-at-the-north-american-box-office/
Link To Post : The top films at the North American Box Office
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment

Read More..

Medicines Co. Licenses Rights to Cholesterol Drug

The drug, known as ALN-PCS, inhibits a protein in the body known as PCSK9. Such drugs might one day be used to treat millions of people who do not achieve sufficient cholesterol-lowering from commonly used statins, such as Lipitor.

The Medicines Company will pay $25 million initially and as much as $180 million later if certain development and sales goals are met, under the deal expected to be formally announced Monday. It will also pay Alnylam, which is based in Cambridge, Mass., double-digit royalties on global sales.

That is small payment for a drug with presumably a huge potential market, probably reflecting that Alnylam is still in the first of three phases of clinical trials, well behind some far bigger competitors.

The team of Sanofi and Regeneron Pharmaceuticals is already entering the third and final stage of trials with their PCSK9 inhibitor, as is Amgen. Pfizer and Roche are in midstage trials.

ALN-PCS is different from the other drugs. It uses a gene-silencing mechanism called RNA interference, aimed at shutting off production of the PCSK9 protein. The other drugs are proteins called monoclonal antibodies that inhibit the action of PCSK9 after it has been formed.

Alnylam and the Medicines Company hope that turning off the faucet, as it were, will be more efficient than mopping the floor, allowing their drug to be given less frequently and in smaller amounts.

But that has yet to be proved. No drug using RNA interference has reached the market.

The Medicines Company, based in Parsippany, N.J., generates almost all of its revenue from one product — Angiomax, an anticlotting drug used when patients receive stents to open clogged arteries.

Dr. Clive A. Meanwell, chief executive of the company, said that PCSK9 inhibitors are likely to be used at first mainly by patients with severe lipid problems under the care of interventional cardiologists, the same doctors who use Angiomax. “It really is quite adjacent to what we do,” he said.

The Medicines Company licensed Angiomax from Biogen Idec, where the drug was invented and initially developed under a team led by Dr. John M. Maraganore, who is now the chief executive of Alnylam.

“It’s a bit like getting the band back together,” Dr. Maraganore said.

Read More..

Medicines Co. Licenses Rights to Cholesterol Drug

The drug, known as ALN-PCS, inhibits a protein in the body known as PCSK9. Such drugs might one day be used to treat millions of people who do not achieve sufficient cholesterol-lowering from commonly used statins, such as Lipitor.

The Medicines Company will pay $25 million initially and as much as $180 million later if certain development and sales goals are met, under the deal expected to be formally announced Monday. It will also pay Alnylam, which is based in Cambridge, Mass., double-digit royalties on global sales.

That is small payment for a drug with presumably a huge potential market, probably reflecting that Alnylam is still in the first of three phases of clinical trials, well behind some far bigger competitors.

The team of Sanofi and Regeneron Pharmaceuticals is already entering the third and final stage of trials with their PCSK9 inhibitor, as is Amgen. Pfizer and Roche are in midstage trials.

ALN-PCS is different from the other drugs. It uses a gene-silencing mechanism called RNA interference, aimed at shutting off production of the PCSK9 protein. The other drugs are proteins called monoclonal antibodies that inhibit the action of PCSK9 after it has been formed.

Alnylam and the Medicines Company hope that turning off the faucet, as it were, will be more efficient than mopping the floor, allowing their drug to be given less frequently and in smaller amounts.

But that has yet to be proved. No drug using RNA interference has reached the market.

The Medicines Company, based in Parsippany, N.J., generates almost all of its revenue from one product — Angiomax, an anticlotting drug used when patients receive stents to open clogged arteries.

Dr. Clive A. Meanwell, chief executive of the company, said that PCSK9 inhibitors are likely to be used at first mainly by patients with severe lipid problems under the care of interventional cardiologists, the same doctors who use Angiomax. “It really is quite adjacent to what we do,” he said.

The Medicines Company licensed Angiomax from Biogen Idec, where the drug was invented and initially developed under a team led by Dr. John M. Maraganore, who is now the chief executive of Alnylam.

“It’s a bit like getting the band back together,” Dr. Maraganore said.

Read More..

'Argo' director Ben Affleck Wins DGA Award

Ben Affleck was named outstanding director for "Argo" at the 65th Annual Directors Guild of America Awards, which were held Saturday night at the Ray Dolby Ballroom at Hollywood & Highland.

The win solidifies "Argo" as an Oscar frontrunner, after the film also claimed key honors from the Screen Actors and Producers guilds last weekend.

"I don't this makes me a real director, but I think it means I'm on my way," Affleck said in a speech.

The other nominees for the feature directing award were Kathryn Bigelow for "Zero Dark Thirty," Tom Hooper for "Les Miserables," Ang Lee for "Life of Pi" and Steven Spielberg for "Lincoln."

The DGA award for feature directing has traditionally been a reliable indicator of who will win the directing Oscar -- only six times since the DGA Awards began in 1948 have the two honors differed.

But this year's Oscar directing race has been a bit of a head-scratcher--Affleck was not nominated, despite his film receiving multiple nominations from the Academy in other categories. Bigelow and Hooper were also snubbed.

The DGA is a larger body than the Academy's directing branch, representing 15,000 members, many of them in television.

The ceremony's television winners included Rian Johnson, who earned the drama series award for directing the "Fifty-One" episode of "Breaking Bad"; Lena Dunham, who collected the comedy series award for directing the pilot of "Girls"; and Jay Roach, who took the movies for television/miniseries prize for "Game Change" on HBO.

The evening's winner for documentary directing was Malik Bendjelloul, for the "Searching For Sugarman."

A lifetime achievement award was presented to "One Flew Over the Cuckoo's Nest" and "The People vs. Larry Flynt" director Milos Forman.

Host Kelsey Grammer kept the evening light, making jokes about Manti Te'o, Mel Gibson and Ron Jeremy, as well as some of the nominees in the room.

Grammer said to Bigelow, whose movie has been at the center of a controversy over forced interrogation, "Waiting so patiently to see if your name will be called, it must be torture for you."

All of the evening's feature directing nominees received a medallion from the DGA, most of them presented after an adoring speech. Martin Short, however, delivered Spielberg's medallion in an irreverent and sometimes bawdy address.

"I like my champagne like I like my women," Short said. "Compliments of the DGA."

When Spielberg stood to accept the honor--receiving the night's first full-house standing ovation--he reacted with amusement.

"When you tell your assistant to contact Marty about presenting you with the DGA medallion," Spielberg said, "You just assume she knows you're talking about Marty Scorsese."

ALSO

Academy doesn't follow the script in directors' race

Santa Barbara Film Fest sees itself as Oscar harbinger

Is 'Argo' poised to deliver a shocker at Directors Guild Awards?

Read More..

The World's Tweets Light Up the Globe in Stunning Live Visualization

It’s simple, but lovely. Web designer Franck Ernewein‘s real-time Twitter visualization, Tweetping, drops a bright pixel at the location of every tweet in the world, starting as soon as you open the page.

The result is a constantly changing image that grows to look like a nighttime satellite shot, bright spots swarming over the most developed areas. But Ernewein has packaged it all in a subtly interactive visualization that avoids distracting the viewer while still imparting a great amount of information.

Meanwhile, a selection of tweets are projected, along with latest hashtags and mentions, all while tracking total tweets, words, and characters. The length of the two gray lines on the display represent the number of characters and words in each tweet.

Though it’s one of the most beautiful, Tweetping is far from the first to display geotagged tweet information; coders have built sites to display election tweets, adjustable parameter maps, and even 3-D visualizations.

Tweetping even represents Antarctica, but not the ISS. And there’s no pause button; like Twitter itself, Tweetping’s data accrues incessantly; there’s no off switch but the back button.

Read More..